natgillin/translations-raw huggingface dataset:
Ryst hætteglasset kraftigt i mindst 30 sekunder, indtil suspensionen ser ensartet ud. 
Shake the vial vigorously for at least 30 seconds until the suspension appears uniform.
Samtidig med den næste injektion skal der administreres oralt aripiprazol i 14 dage, og derefter genoptages den månedlige injektion. 
Concomitant oral aripiprazole should be restarted for 14 days with next administered injection and then resume monthly injection schedule.
Vægtøgning er rapporteret efter markedsføring hos patienter behandlet med oralt aripiprazol. 
Weight gain has been reported post-marketing among patients prescribed oral aripiprazole.
Orofaryngeale spasmer Laryngospasmer Aspirationspneumoni 
Oropharyngeal spasm Laryngospasm Aspiration pneumonia
Forhøjet blodsukker Lavt blodsukker Forhøjet glykosyleret hæmoglobin 
Blood glucose increased Blood glucose decreased Glycosylated haemoglobin increased
Inden du bliver behandlet med Abilify Maintena, skal du fortælle lægen, om følgende lidelser og forhold er gældende for dig: 
Before treatment with Abilify Maintena, tell your doctor if you suffer from
Husk at skifte injektionssted, så der veksles mellem de to gluteal- eller deltoidmuskler. 
Remember to rotate sites of injections between the two gluteal or deltoid muscles.
- Aktivt stof: aripiprazol 
- The active substance is aripiprazole.
Det skal du vide om Abilify Maintena Du må ikke få Abilify Maintena: 
What you need to know before you are given Abilify Maintena Do not use Abilify Maintena:
Andre potente CYP3A4-hæmmere som fx itraconazol og HIV-protease-hæmmere kan forventes at have lignende virkninger, og derfor skal dosis reduceres tilsvarende (se pkt. 
Other strong inhibitors of CYP3A4, such as itraconazole and HIV protease inhibitors may be expected to have similar effects and similar dose reductions should, therefore, be applied (see section 4.2).
Injektionsvolumen 
Volume to Inject
Abilify Maintena 300 mg pulver og solvens til depotinjektionsvæske, suspension EU/1/13/882/001 
Abilify Maintena 300 mg powder and solvent for prolonged-release suspension for injection EU/1/13/882/001
Hos langsomme CYP2D6-omsættere kan samtidig brug af potente CYP3A4-hæmmere medføre højere plasmakoncentrationer af aripiprazol end hos hurtige CYP2D6-omsættere (se pkt. 
In CYP2D6 poor metabolisers, concomitant use of strong inhibitors of CYP3A4 may result in higher plasma concentrations of aripiprazole compared to that in CYP2D6 extensive metabolisers (see section 4.2).
Samtidig brug af CYP3A4-induktorer og Abilify Maintena i mere end 14 dage skal undgås, da blodets indhold af aripiprazol reduceres og kan nedsættes til under det virksomme niveau (se pkt. 
Concomitant use of CYP3A4 inducers with Abilify Maintena should be avoided for more than 14 days because the blood levels of aripiprazole are decreased and may be below the effective levels (see section 4.5).
Hyperglykæmi Hyperkolesterolæmi Hyperinsulinæmi Hyperlipidæmi Hypertriglyceridæmi Appetitforstyrrelser 
Hyperglycaemia Hypercholesterolaemia Hyperinsulinaemia Hyperlipidaemia Hypertriglyceridaemia Appetite disorder
• ufrivillige, uregelmæssige muskelbevægelser, især i ansigtetoplever en kombination af feber, 
• involuntary, irregular muscle movements, especially in the face
Kun til dyb intramuskulær injektion i gluteal- eller deltoidmusklen. 
For deep intramuscular gluteal or deltoid injection only.
Fluktuerende blodsukkerniveau 
Blood glucose fluctuation
• Brystforstørrelser hos mænd, ømme bryster, tørhed i skeden 
• enlargement of breast in men, breast tenderness, vaginal dryness
• svære problemer med leveren. 
• severe liver problems.
Når svage CYP3A4-hæmmere (fx diltiazem) eller CYP2D6-hæmmere (fx escitalopram) bruges samtidig med dette lægemiddel, kan en lille stigning i plasmakoncentrationen af aripiprazol forventes. 
When weak inhibitors of CYP3A4 (e.g. diltiazem) or CYP2D6 (e.g. escitalopram) are used concomitantly with aripiprazole, modest increases in plasma aripiprazole concentrations may be expected.
• Søvnforstyrrelser 
• sleep disorder
Abilify Maintena leveres i en fyldt injektionssprøjte, der indeholder et hvidt til råhvidt pulver i forkammeret og en klar solvens i bagkammeret. 
Abilify Maintena comes in a pre-filled syringe containing a white to off-white powder in the front chamber and a clear solvent in the rear chamber.
I et enkeltdosisstudie med oral administration af aripiprazol havde aripiprazol og dehydroaripiprazol de samme farmakokinetiske egenskaber hos patienter med svær nyresygdom som hos raske unge. 
In a single-dose study with oral administration of aripiprazole, the pharmacokinetic characteristics of aripiprazole and dehydro-aripiprazole were found to be similar in patients with severe renal disease compared to that in young healthy subjects.
Kinidin og andre potente CYP2D6-hæmmere 
Quinidine and other strong CYP2D6 inhibitors
• antidepressiva (fx venlafaxin og tryptophan) til behandling af svær depression 
• other anti-depressants (such as venlafaxine and tryptophan) used in major depression
Tardiv dyskinesi Parkinsonisme Bevægeforstyrrelser Psykomotorisk hyperaktivitet Uro i benene Tandhjulsrigiditet Hypertoni Bradykinesi Savlen 
Tardive dyskinesia Parkinsonism Movement disorder Psychomotor hyperactivity Restless legs syndrome Cogwheel rigidity Hypertonia
Kontakt lægen eller sundhedspersonalet, før du bruger Abilify Maintena. 
Talk to your doctor or nurse before you are given Abilify Maintena.
• Rysten eller skælven 
• shaking or trembling
Vægtøgning ≥ 7 % fra baseline til sidste besøg (uge 12) forekom hos 21,5 % i Abilify Maintena-gruppen og hos 8,5 % i placebogruppen. 
The incidence of weight gain of ≥ 7 % from baseline to last visit (week 12) was 21.5 % for Abilify Maintena compared with the placebo group 8.5 %.
Ét hætteglas med 2 ml solvens To sterile sprøjter, den ene med nål til rekonstitution Tre hypodermiske sikkerhedskanyler Én hætteglasadapter 
Two sterile syringes, one with needle for reconstitution Three hypodermic safety needles One vial adapter
I de dobbeltblinde, kontrollerede faser i de to langvarige studier blev der observeret reaktioner på injektionsstedet. 
During the double-blind, controlled phases of the two long-term trials, injection site reactions were observed; those seen were generally mild to moderate in severity, and resolved over time.
ARIP IMD 400/300 mg vs. ARIP 10-30 mg: p-værdi 0,9920 ARIP IMD 400/300 mg vs. ARIP IMD 50/25 mg: p-værdi < 0,0001 
ARIP IMD 400/300 mg vs. ARIP 10-30 mg: p value 0.9920 ARIP IMD 400/300 mg vs. ARIP IMD 50/25 mg: p value < 0.0001
I den dobbeltblinde placebokontrollerede fase af det 52 uger lange studie var der fra baseline til sidste besøg et gennemsnitligt fald i prolaktinniveauet i den gruppe, der fik Abilify Maintena (−0,38 ng/ml), sammenholdt med en gennemsnitlig stigning i placebogruppen (1,67 ng/ml). 
In the Double-blind Placebo-controlled Phase of the 52-week trial, from baseline to last visit there was a mean decrease in prolactin levels in Abilify Maintena (−0.38 ng/ml) compared with a mean increase in placebo (1.67 ng/ml).
I et klinisk studie med raske forsøgspersoner, der fik oralt aripiprazol, øgede en potent CYP3A4hæmmer (ketoconazol) aripiprazols AUC og Cmax med henholdsvis 63 % og 37 %. 
In a clinical trial of oral aripiprazole in healthy subjects, a strong inhibitor of CYP3A4 (ketoconazole) increased aripiprazole AUC and Cmax by 63 % and 37 %, respectively.
Når CYP2D6- eller CYP3A4-hæmmeren seponeres, skal aripiprazol-dosis atter øges til den dosis, der var gældende, inden den samtidige behandling blev påbegyndt. 
Upon discontinuation of the CYP2D6 or CYP3A4 inhibitor, the dosage of aripiprazole should be increased to the dose prior to the initiation of the concomitant therapy.
d) Bestem injektionsvolumen i henhold til dosisanbefalingerne. 
d) Determine the recommended volume for injection.
Efter administration af en enkelt dosis Abilify Maintena i henholdsvis deltoid- og glutealmusklen var absorptionen (AUC) den samme for begge injektionssteder, men absorptionshastigheden (Cmax) var større efter administration i deltoidmusklen. 
The dose adjusted Cmax values for the depot formulation were approximately 5 % of Cmax from IM standard formulation.Following a single dose administration of Abilify Maintena in the deltoid and gluteal muscle, the extent of absorption (AUC) was similar for both injection sites, but the rate of absorption (Cmax) was higher following administration to the deltoid muscle.
- højere niveau af triglycerider i blodet 
- lower amounts of triglycerides in your blood
Brug af anden medicin sammen med Abilify Maintena 
Other medicines and Abilify Maintena
• Ekstrem rastløshed og uro i benene 
• extreme restlesness and restless legs
Lægen injicerer lægemidlet som én injektion i din sæde- eller deltamuskel (ballen eller skulderen) hver måned. 
Your doctor will give it to you as a single injection into the gluteal or deltoid muscle (buttock or shoulder) every month.
(tandhjulsrigiditet), hurtige skridt, rystelser, ingen eller meget få ansigtsudtryk, muskelstivhed, 
shuffling, hurried steps, shaking, little or no facial expression, muscle stiffness, drooling
Smerter på injektionsstedet Induration på injektionsstedet Fatigue 
Injection site induration Fatigue
Tilsvarende havde alderen i en farmakokinetisk populationsanalyse af Abilify Maintena til skizofrene patienter ingen målbar indvirkning. 
Similarly, there was no detectable effect of age in a population pharmacokinetic analysis of Abilify Maintena in schizophrenia patients.
• Allergisk reaktion (fx hævelse i munden, af tungen, i ansigtet og i halsen, kløe, nældefeber), udslæt 
• allergic reaction (e.g. swelling in the mouth, tongue, face and throat, itching, hives), rash
Justering af Abilify Maintena-dosis hos patienter, der samtidig tager potente CYP2D6hæmmere, potente CYP3A4-hæmmere og/eller CYP3A4-induktorer i mere end 14 dage 
Dose adjustments of Abilify Maintena in patients who are taking concomitant strong CYP2D6 inhibitors, strong CYP3A4 inhibitors, and/or CYP3A4 inducers for more than 14 days
Din læge eller sygeplejerske vil opblande pulveret i et andet klart hætteglas, der indeholder Abilify Maintenasolvensen, hvorefter du vil få injiceret suspensionen (det opblandede præparat). 
Your doctor or nurse will make it into a suspension that will be given as an injection using the vial of solvent for Abilify Maintena that comes as a clear solution in a clear glass vial.
Type I-hætteglas, der er lukket med en lamineret gummiprop og forseglet med en afrivelig aluminiumshætte. 
Vial Type-I glass vial stoppered with a laminated rubber stopper and sealed with a flip-off aluminium cap.
b) Tag sprøjten med påsat kanyle, og træk den korrekte mængde solvens op i sprøjten fra hætteglasset med solvens. 
b) Using the syringe with pre-attached needle, withdraw the pre-determined solvent volume from the vial of the solvent into the syringe.
Carmellosenatrium, mannitol, natriumdihydrogenphosphatmonohydrat, natriumhydroxid Solvens 
Carmellose sodium, mannitol, sodium dihydrogen phosphate monohydrate, sodium hydroxide Solvent
Nedsat nyrefunktion Det er ikke nødvendigt at justere dosis hos patienter med nedsat nyrefunktion (se pkt. 
Renal impairment No dosage adjustment is required for patients with renal impairment (see section 5.2).
Overvægtig Deltoidmusklen 38 mm og 22 gauge Glutealmusklen 51 mm og 21 gauge c) Indgiv langsomt den anbefalede mængde som en enkelt intramuskulær injektion i gluteal- eller deltoidmusklen. 
51 mm (2 inch) 21 gauge c) Slowly inject the recommended volume as a single intramuscular injection into the gluteal or deltoid muscle.
Type I-hætteglas (2 ml), der er lukket med en lamineret gummiprop og forseglet med en afrivelig aluminiumshætte. 
2 ml Type-1 glass vial stoppered with a laminated rubber stopper and sealed with a flip-off aluminium cap.
I placebogruppen sås imminent recidiv hos 39,6 % af patienterne, mens der i Abilify Maintena-gruppen sås imminent recidiv hos 10 % af patienterne. 
In the placebo group 39.6 % of the patients had progressed to impending relapse, whilst in the Abilify Maintena group impending relapse occurred in 10 % of the patients; thus patients in the placebo group had a 5.03-fold greater risk of experiencing impending relapse.
- højere niveau af glykosyleret hæmoglobin 
- higher amounts of glycosylated haemoglobin
Nedsat prolaktin i blodet Hyperprolaktinæmi 
Blood prolactin decreased Hyperprolactinaemia
Incidensen af prolaktinniveau > 1 x øvre normalværdi (ULN) ved alle målinger var 5,4 % blandt Abilify Maintena-patienter sammenholdt med 3,5 % blandt patienter, der fik oralt aripiprazol 10-30 mg (tabletter). 
The incidence of Abilify Maintena patients with prolactin levels > 1 time the upper limit of normal range (ULN) at any assessment was 5.4 % compared with 3.5 % of the patients on oral aripiprazole tablets 10-30 mg.
Hvis du holder op med at få Abilify Maintena 
If you stop receiving Abilify Maintena
Vigtigt: Der er mere solvens i hætteglasset, end der skal bruges. 
Important: the solvent vial contains an overfill.
Pulver Carmellosenatrium, mannitol, natriumdihydrogenphosphatmonohydrat, natriumhydroxid 
Powder Carmellose sodium, mannitol, sodium dihydrogen phosphate monohydrate, sodium hydroxide
Efter oral administration of aripiprazol er der ingen forskel i aripiprazols farmakokinetik hos raske mandlige og kvindelige patienter. 
After oral administration of aripiprazole, there are no differences in the pharmacokinetics of aripiprazole between healthy male and female subjects.
• Dobbeltsyn 
• double vision
• Nervøsitet 
• nervousness
Hætteglas, adapter, sprøjter, kanyler, ikke-anvendt suspension og vand til injektionsvæsker skal bortskaffes i henhold til lokale retningslinjer. 
Discard vial, adapter, syringe, needles, unused suspension and water for injections appropriately.
Tilsvarende havde kønnet i en farmakokinetisk populationsanalyse af Abilify Maintena i kliniske studier med skizofrene patienter ingen klinisk relevant indvirkning. 
Similarly, there was no clinically relevant effect of gender in a population pharmacokinetic analysis of Abilify Maintena in clinical trials in patients with schizophrenia.
Efter oral administration af aripiprazol er der ingen forskel i aripiprazols farmakokinetik hos raske ældre patienter og raske yngre voksne patienter. 
After oral administration of aripiprazole, there are no differences in the pharmacokinetics of aripiprazole between healthy elderly and younger adult subjects.
Okulogyr krise er ikke nævnt for nogen andre aripiprazol-produkter. 
For all other aripiprazole products, oculogyric crisis is not listed.
Hvis CYP3A4-hæmmeren eller CYP2D6-hæmmeren seponeres, kan det være nødvendigt igen at øge dosis til den oprindelige dosis (se pkt. 
If the CYP3A4 inhibitor or CYP2D6 inhibitor is withdrawn, the dosage may need to be increased to the previous dose (see section 4.5).
Ét hætteglas med pulver 
One vial of powder
Kaplan-Meier-kurver for tiden fra randomisering til imminent recidiv i den 38 uger lange dobbeltblinde og aktivkontrollerede fase er vist for Abilify Maintena, oralt aripiprazol 10-30 mg og aripiprazol-depotinjektion 50 mg/25 mg i figur 1. 
The Kaplan-Meier curves of the time from randomisation to impending relapse during the 38-week, Double-blind, Active-controlled Phase for Abilify Maintena, oral aripiprazole 10-30 mg, and aripiprazole Long-Acting Injectable 50 mg/25 mg are shown in Figure 1.
Nedenstående bivirkninger kan også ses ved injektion af Abilify Maintena. 
The side effects listed below may also occur after receiving Abilify Maintena.
662 patienter, der var egnede til at deltage i den dobbeltblindede, aktivkontrollerede fase over 38 uger, blev randomiseret i forholdet 2:2:1 til dobbeltblindet behandling i en af følgende tre behandlingsgrupper: 1) Abilify Maintena, 2) stabiliseringsdosis af oralt aripiprazol 10-30 mg eller 3) aripiprazol-depotinjektion 50 mg/25 mg. Aripiprazol-depotinjektion 50 mg/25 mg blev inkluderet som en lavdosis-aripiprazol for at teste analysesensitiviteten, for så vidt angår noninferioritetsdesignet. 
Six-hundred and sixty two patients eligible for the 38-week Double-blind, Active-controlled Phase were randomly assigned in a 2:2:1 ratio to double-blind treatment to one of 3 treatment groups: 1) Abilify Maintena 2) the stabilisation dose of oral aripiprazole 10-30 mg, or 3) aripiprazole LongActing Injectable 50 mg/25 mg.
Tilfælde af serotoninsyndrom er rapporteret hos patienter, der tager aripiprazol, og der kan især opstå tegn og symptomer på denne lidelse ved samtidig brug af andre serotonerge lægemidler som fx 
Cases of serotonin syndrome have been reported in patients taking aripiprazole, and possible signs and symptoms for this condition can occur especially in cases of concomitant use with other serotonergic medicinal products, such as SSRI/SNRI, or with medicinal products that are known to increase aripiprazole concentrations (see section 4.8).
• Taleforstyrrelser 
• speech disorders
Dystoniske symptomer kan være spasmer i nakkemusklerne, der i nogle tilfælde kan udvikle sig til en sammensnørende fornemmelse i halsen, synkebesvær, vejrtrækningsbesvær og/eller protrusion af tungen. 
Dystonic symptoms include spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue.
I den dobbeltblinde fase med aktiv kontrol i det langvarige studie på 38 uger var incidensen af en vægtøgning ≥ 7 % fra baseline til sidste besøg på 9,5 % for den gruppe, der fik Abilify Maintena, og på 11,7 % for den gruppe, der fik oralt aripiprazol 10-30 mg (tabletter). 
During the Double-blind, Active-controlled Phase of the 38-week long-term trial, the incidence of weight gain of ≥ 7 % from baseline to last visit was 9.5 % for Abilify Maintena and 11.7 % for the oral aripiprazole tablets 10-30 mg.
• Ændret opmærksomhedsniveau, sløvhed 
• changes in your level of alertness, drowsiness
Uhæmmet madindtagelse (spise store mængder mad i en kort periode) eller overdreven madindtagelse (spise mere mad end sædvanligt og mere end nødvendigt for at dække sulten) 
(eating more food than normal and more than is needed to satisfy your hunger)
Trin 2: Rekonstitution af pulveret a) Tryk let på stemplet, så det griber fat i gevindet. 
Step 2: Reconstitution of the powder a) Push plunger rod slightly to engage threads.
Ved brug af aripiprazol kan der opstå overfølsomhedsreaktioner, der er kendetegnet ved allergiske symptomer (se pkt. 
Hypersensitivity reactions, characterised by allergic symptoms, may occur with aripiprazole (see section 4.8).
• Lysfølsomhed 
• sensitivity to light
• Halsbrand 
• heartburn
Den anbefalede start- og vedligeholdelsesdosis for Abilify Maintena er 400 mg. 
The recommended starting and maintenance dose of Abilify Maintena is 400 mg. Titration of the dose of this medicinal product is not required.
Neutropeni startede typisk omkring dag 16 efter den første injektion og havde en median varighed på 18 dage. 
Neutropenia has been reported in the clinical program with Abilify Maintena and typically started around day 16 after first injection, and lasted a median of 18 days.
Tabel 2 Samlet PANSS-score - ændring fra baseline til uge 10: Analyse baseret på effektpopulationen Samlet PANSS-score - ændring fra baseline til uge 10: Analyse baseret på effektpopulationena Abilify Maintena 400 mg/300 mg 
PANSS Total Score - Change From Baseline to Week 10: Randomised Efficacy Sample a Abilify Maintena 400 mg/300 mg
• visse lægemidler mod HIV (fx efavirenz, nevirapin, indinavir eller ritonavir 
• certain medicines to treat HIV infection (such as efavirenz, nevirapine, and protease inhibitors e.g. indinavir, ritonavir)
BEMÆRK: ARIP IMD 400/300 mg = Abilify Maintena;ARIP 10-30 mg = oralt aripiprazol; ARIP IMD 50/25 mg = depotinjektion 
NOTE: ARIP IMD 400/300 mg = Abilify Maintena;ARIP 10-30 mg = oral aripiprazole; ARIP IMD 50/25 mg = Long-acting Injectable
Der vil stadig være en lille mængde suspension tilbage i hætteglasset. 
A small amount of excess product will remain in the vial.
Hætteglassene med pulver og solvens er kun til engangsbrug. 
The powder and solvent vials are for single-use only.
Én fyldt injektionssprøjte, der indeholder pulver i forkammeret og solvens i bagkammeret. 
One pre-filled syringe containing powder in the front chamber and solvent in the rear chamber.
Galaktorré Gynækomasti Ømhed i brysterne Vulvovaginal tørhed 
Galactorrhoea Gynaecomastia Breast tenderness Vulvovaginal dryness
Du skal tage aripiprazol i tabletform i 14 dage efter den første injektion. 
Treatment with aripiprazole by mouth is continued for 14 days after the first injection.
Dette kan være tegn på en blodprop, der kan blive ført op til lungerne gennem blodkarrene og forårsage brystsmerter og vejrtrækningsbesvær. 
pain and redness in the leg), which may travel through blood vessels to the lungs causing chest pain and difficulty in breathing
Der skal udvises forsigtighed, hvis aripiprazol administreres samtidig med lægemidler, der giver QTforlængelse eller elektrolytforstyrrelser. 
If aripiprazole is administered concomitantly with medicinal products known to cause QT prolongation or electrolyte imbalance, caution should be used.
Aripiprazol har i kliniske studier ikke induceret klinisk relevant vægtøgning (se pkt. 
In clinical trials aripiprazole has not been shown to induce clinically relevant weight gain (see section 4.8).
I et enkeltdosisstudie med oral administration af aripiprazol til patienter med varierende grader af levercirrose (Child-Pugh-klasse A, B og C) fandt man ingen tegn på, at nedsat leverfunktion skulle have nogen signifikant indvirkning på aripiprazols og dehydroaripiprazols farmakokinetik. 
A single-dose study with oral administration of aripiprazole to subjects with varying degrees of liver cirrhosis (Child-Pugh Classes A, B, and C) did not reveal a significant effect of hepatic impairment on the pharmacokinetics of aripiprazole and dehydro-aripiprazole, but the study included only 3 patients with Class C liver cirrhosis, which is insufficient to draw conclusions on their metabolic capacity.
Bortskaf hætteglas, adapter, kanyler og sprøjte efter injektionen i henhold til lokale retningslinjer. 
Dispose of the vials, adapter, needles, and syringe appropriately after injection.
Incidensen af prolaktinniveau > 1 x øvre normalværdi (ULN) var 1,9 % blandt Abilify Maintena-behandlede patienter sammenholdt med 7,1 % blandt placebobehandlede patienter. 
The incidences of Abilify Maintena patients with prolactin levels > 1 time the upper limit of normal range (ULN) was 1.9 % compared to 7.1 % for placebo patients.
I den dobbeltblinde fase med aktiv kontrol af det 38 uger lange studie var der fra baseline til sidste besøg et gennemsnitligt fald i prolaktinniveauet i den gruppe, der fik Abilify Maintena (-0,33 ng/ml), sammenholdt med en gennemsnitlig stigning i den gruppe, der fik oralt aripiprazol 10-30 mg (tabletter) (0,79 ng/ml; p < 0,01). 
In the Double-blind, Active-controlled Phase of the 38-week trial, from baseline to last visit there was a mean decrease in prolactin levels in Abilify Maintena (−0.33 ng/ml) compared with a mean increase in oral aripiprazole tablets 10-30 mg (0.79 ng/ml; p < 0.01).
Oplever du uventede virkninger, mens du tager en af disse typer medicin sammen med Abilify Maintena, skal du kontakte din læge. 
These medicines may increase the risk of side effects; if you get any unusual symptom taking any of these medicines together with Abilify Maintena, you should see your doctor.
• Symptomer, der er relateret til blodpropper i venerne, især i benene (symptomerne omfatter hævelse, smerter og rødme på benet), der kan vandre gennem blodårerne til lungerne, hvor de medfører brystsmerter og vejrtrækningsbesvær 
• if you have symptoms such as swelling, pain, and redness in the leg, because this may mean you have a blood clot, which may travel through blood vessels to the lungs causing chest pain and difficulty in breathing.
Bortskaf f) Ryst hætteglasset kraftigt i mindst 30 sekunder, indtil suspensionen er ensartet. 
Discard f) Shake the vial vigorously for 30 seconds until the suspension appears uniform.
• smertestillende midler (fx tramadol og pethidin) til lindring af smerter 
• painkillers (such as tramadol and pethidine) used for pain relief